A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- PMID: 18188694
- DOI: 10.1007/s10549-007-9885-0
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
Abstract
Purpose: Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab. Updated efficacy and initial biomarker results from this trial are reported.
Methods: Women with HER2-positive, locally advanced or metastatic breast cancer previously treated with anthracycline-, taxane-, and trastuzumab-containing regimens were randomized to lapatinib 1,250 mg/day continuously plus capecitabine 2,000 mg/m(2) days 1-14 of a 21-day cycle or capecitabine 2,500 mg/m(2) on the same schedule. The primary endpoint was time to progression (TTP) as determined by an independent review panel. Relationship between progression-free survival (PFS) and tumor HER2 expression and serum levels of HER2 extracellular domain (ECD) were assessed.
Results: 399 women were randomized. The addition of lapatinib prolonged TTP with a hazard ratio (HR) of 0.57 (95% CI, 0.43-0.77; P < 0.001) and provided a trend toward improved overall survival (HR: 0.78, 95% CI: 0.55-1.12, P = 0.177), and fewer cases with CNS involvement at first progression (4 vs. 13, P = 0.045). Baseline serum HER2 ECD did not predict for benefit from lapatinib.
Conclusion: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy. Biomarker studies could not identify a subgroup of patients who failed to benefit from the addition of lapatinib to capecitabine.
Comment in
-
Ten years of HER2-directed therapy: still questions after all these years.Breast Cancer Res Treat. 2009 Jan;113(2):207-9. doi: 10.1007/s10549-008-0041-2. Epub 2008 May 8. Breast Cancer Res Treat. 2009. PMID: 18463974 No abstract available.
Similar articles
-
Lapatinib for the treatment of HER2-overexpressing breast cancer.Health Technol Assess. 2009 Oct;13 Suppl 3:1-6. doi: 10.3310/hta13suppl3/01. Health Technol Assess. 2009. PMID: 19846022 Review.
-
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Clin Ther. 2008. PMID: 18803986 Review.
-
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.Oncologist. 2008 Oct;13(10):1114-9. doi: 10.1634/theoncologist.2008-0816. Epub 2008 Oct 10. Oncologist. 2008. PMID: 18849320 Clinical Trial.
-
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.Cancer. 2014 Mar 1;120(5):642-51. doi: 10.1002/cncr.28465. Epub 2013 Nov 12. Cancer. 2014. PMID: 24222194 Clinical Trial.
-
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.J Clin Oncol. 2015 May 10;33(14):1564-73. doi: 10.1200/JCO.2014.57.1794. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605838 Clinical Trial.
Cited by
-
Thoughts on therapy strategy in the era of "after anti-HER2 TKI" in CSCO BC Guidelines 2022.Transl Breast Cancer Res. 2022 Jul 30;3:26. doi: 10.21037/tbcr-22-32. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751519 Free PMC article. Review.
-
A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer.MedComm (2020). 2024 Mar 10;5(3):e505. doi: 10.1002/mco2.505. eCollection 2024 Mar. MedComm (2020). 2024. PMID: 38469548 Free PMC article.
-
Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma.Cancer Commun (Lond). 2023 Dec;43(12):1326-1353. doi: 10.1002/cac2.12502. Epub 2023 Nov 2. Cancer Commun (Lond). 2023. PMID: 37920878 Free PMC article.
-
Leveraging translational insights toward precision medicine approaches for brain metastases.Nat Cancer. 2023 Jul;4(7):955-967. doi: 10.1038/s43018-023-00585-0. Epub 2023 Jul 24. Nat Cancer. 2023. PMID: 37491527 Free PMC article. Review.
-
Computational Methods Summarizing Mutational Patterns in Cancer: Promise and Limitations for Clinical Applications.Cancers (Basel). 2023 Mar 24;15(7):1958. doi: 10.3390/cancers15071958. Cancers (Basel). 2023. PMID: 37046619 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous